Tirofiban increases soluble guanylate cyclase in rat vascular walls: Pharmacological and pathophysiological consequences

Cardiovascular Research

Volumn 82, Issue 1, 2009, Pages 125-132

  Ruiz Torres, María P ^a   Griera, Mercedes ^a   Chamorro, Aránzazu ^a   Díez Marqués, María L ^a   Rodríguez Puyol, Diego ^a,b   Rodríguez Puyol, Manuel ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Arterial pressure; Integrin; Nitric oxide; Nitric oxide donors; RGD motifs; Soluble guanylate cyclase

Indexed keywords

GUANOSINE PHOSPHATE; GUANYLATE CYCLASE; ISOSORBIDE DINITRATE; MESSENGER RNA; NATRIURETIC PEPTIDE RECEPTOR B; NITROPRUSSIDE SODIUM; SOLUBLE GUANYLATE CYCLASE BETA 1 SUBUNIT; TIROFIBAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AORTA; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL WALL; DOWN REGULATION; ENZYME REGULATION; IMMUNOBLOTTING; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; RAT; SMOOTH MUSCLE FIBER; SPHYGMOMANOMETER; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; VASCULAR SMOOTH MUSCLE; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; HUMANS; HYPERTENSION; ISOSORBIDE DINITRATE; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE DONORS; NITROPRUSSIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TACHYPHYLAXIS; TIME FACTORS; TYROSINE; UP-REGULATION; VASODILATION; VASODILATOR AGENTS;

EID: 62349099638     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn359     Document Type: Article

References (39)

1. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart L, Park J, Schulz S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-413.
2. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999;85:534-541.
3. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004;101:16671-16676.
4. Courtois E, Marques M, Barrientos A, Casado S, Lopez-Farre A. Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 2003;14:1464-1470.
5. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997;100:942-948.
6. Rossoni G, Manfredi B, Del Soldato P, Berti F. The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. J Pharmacol Exp Ther 2004;310:555-562.
7. Scatena R, Bottoni P, Martorana GE, Giardina B. Nitric oxide donor drugs: an update on pathophysiology and therapeutic potential. Expert Opin Investig Drugs 2005;14:835-846.
8. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002;137:295-310.
9. Pak T, Cadet P, Mantione KJ, Stefano GB. Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. Med Sci Monit 2005;11:BR357-366.
10. Díez-Marqués ML, Ruiz-Torres MP, Griera M, Lopez-Ongil S, Saura M, Rodríguez-Puyol D et al. Arg-Gly-Asp (RGD)-containing peptides increase soluble guanylate cyclase in contractile cells. Cardiovasc Res 2006;69:359-369.
11. Proimos G. Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombolysis 2001;11:99-110.
12. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptied inhibitor of the platelet glycoprotein IIb-IIIa receptor. In: Sasahara AA, Loscazo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker; 1997. p355-365.
13. Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA et al. Platelet glycoprotein IIb-IIIa antagonists from snake venom: Evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci USA 1990;87:2471-2475.
14. Aguzzi MS, Facchiano F, Ribatti D, Gaeta R, Casadio R, Rossi I et al. A novel RGDS-analog inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2004;321:809-814.
15. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 1995;92:6161-6165.
16. Ortega-Velazquez R, Díez-Marqués ML, Ruiz-Torres MP, Gonzalez-Rubio M, Rodríguez-Puyol M, Rodríguez-Puyol D. Arg-Gly-Asp-Ser (RGDS) peptide stimulates transforming growth factor beta1 transcription and secretion through integrin activation. FASEB J 2003;11:1529-1531.
17. Perez-Rivero G, Ruiz-Torres MP, Rivas-Elena JV, Jerkic M, Díez-Marqués ML, Lopez-Novoa JM et al. Mice deficient in telomerase activity develop hypertension because of an excess of endothelin production. Circulation 2006;114:309-317.
18. Rodríguez-Mañas L, Arribas S, Giron MC, Villamor J, Sanchez-Ferrer CF, Marin J. Interference of glycosylated human hemoglobin with endothelium-dependent responses. Circulation 1993;88:2111-2116.
19. Peiro C, Lafuente N, Matesanz N, Cercas E, Llergo JL, Vallejo S et al. High glucose induces cell death of human aortic smooth muscle cells through the formation of hydrogen peroxide. Br J Pharmacol 2001;133:967-974.
20. Garcia-Escribano C, Díez-Marqués ML, Gonzalez-Rubio M, Rodríguez-Puyol M, Rodríguez-Puyol D. Somatostatin antagonizes angiotensin II effects of mesangial cell contraction and glomerular filtration. Kidney Int 1993;43:324-333.
21. De Frutos S, Saura M, Griera M, Rivero-Vilches FJ, Zaragoza C, Rodríguez-Puyol D et al. Differential regulation of soluble guanylyl cyclase expression and signaling by collagens: involvement of integrin-linked kinase. J Am Soc Nephrol 2005;16:2626-2635.
22. Chomczynski P, Sacchi N. Single-step methods of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
23. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002;110:673-687.
24. Thom SR, Bhopale VM, Han ST, Clark JM, Hardy KR. Intravascular neutrophil activation due to carbon monoxide poisoning. Am J Respir Crit Care Med 2006;174:1239-1248.
25. Basani RB, Zhu H, Thornton MA, Soto CS, Degrado WF, Kowaslska MA et al. Species differences in small molecule binding to αIIb β3 are due to sequence differences in two loops of the aIIb b propeller. Blood Advanced Access published November 5 2008; doi:10.1182/blood-2008-09-177337.
26. Szocs K, Lassegue B, Wenzel P, Wendt M, Daiber A, Oelze M et al. Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation. J Mol Cell Cardiol 2007;42:1111-1118.
27. Hassoun PM, Filippov G, Fogel M, Donaldson C, Kayyali US, Shimoda LA et al. Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2004;30:908-913.
28. Kagota S, Tamashiro A, Yamaguchi Y, Nakamura K, Kunitomo M. High salt intake impairs vascular nitric oxide/cyclic guanosine monophosphate system in spontaneously hypertensive rats. J Pharmacol Exp Ther 2002;302:344-351.
29. Takata M, Filippov G, Liu H, Ichinose F, Janssens S, Bloch DB et al. Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001;280:L272-L278.
30. Heitzer T, Ollman I, Koke K, Meinertz T, Munzel T. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patient with coronary artery disease. Circulation 2003;108:536- 541.
31. Sayed N, Baskaran P, Ma X, van den Akker F, Beuve A. Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc Natl Acad Sci USA 2007;104:12312-12317.
32. Cheng JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther 2006;28:666-678.
33. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-295.
34. Kloss S, Bouloumie A, Mulsch A. Aging and chronic hypertension decrease expression of rat aortic soluble guanylyl cyclase. Hypertension 2000;35:43-47.
35. Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens 2003;21:1117-1124.
36. Boerrigter G, Burnett JC. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007;25:30-45.
37. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP et al. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006;48:972-978.
38. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003;107:686-689.
39. Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H et al. Stimulation of soluble guanylate cyclase slows progression in anti-thy-1-induced chronic glomerulosclerosis. Kidney Int 2005;68:47-61.